Boston Scientific announced its Board of Directors has approved a new global restructuring program, the "2026 Restructuring Plan," designed to drive sustained cost efficiencies and support strategic growth initiatives. The plan involves supply chain optimization, organizational changes, and functional transformations, which are expected to result in some headcount reductions.
Key Details
- Total Estimated Cost: The company projects total pre-tax charges of $700 million to $800 million, with $600 million to $700 million expected in cash outlays.
- Projected Annual Savings: The program is expected to reduce gross annual pre-tax expenses by approximately $500 million once fully implemented, with a significant portion to be reinvested.
- Timeline: The restructuring activities will be initiated in 2026 and are expected to be substantially completed by the end of 2029.
- Cost Breakdown: Major estimated charges include $300-$350 million for transfer costs, $275-$300 million for employee termination benefits, and $125-$150 million for other related expenses.